Compare Kraft Heinz Co (KHC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Pfizer Inc — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 5.9× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Pfizer Inc for 158 Days on average.
| KHC | PFE | |
|---|---|---|
Market Cap | $26.66B | $158.56B |
Volume | 31,300,109 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $29.02 |
52-Week Low | $21.21 | $23.67 |
Typical Hold Time | 129 Days | 158 Days |
Enterprise Value | $42.98B | $210.06B |
Dividend Yield | 7.12% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.48, up 2.27% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a low P/E of 13.04 and P/B of 0.74, but negative net income and ROE reflect profitability challenges. Recent earnings have beaten estimates, and the company maintains a $0.40 dividend. Cash flow improved in 2025, though revenue declined to $24.94 billion. News highlights turnaround efforts, including new product launches and a halted breakup plan.
The outlook is cautious; while valuation appears cheap and dividends attract income investors, persistent negative margins and high debt pose risks. Analyst consensus is mixed with a $24.50 price target, but bearish sentiment and competitive pressures suggest limited near-term upside. Investors should weigh the dividend yield against execution risks in the consumer goods sector.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
